"bioassay," to indicate if E 2 levels are sufficiently sup-14. Tsuji K, Narahara K, Yokoyama Y, Grzeschik KH, Kunz J: The breakpoint on 7p in a patient with t(6;7) and craniosynostosis is pressed prior to commencing COH (2).
spanned by a YAC clone containing the D7S503 locus. Hum
In an effort to further simplify surveillance proto- serum E 2 levels. Functional and nonfunctional cysts with a diameter ated in order to document pituitary "down-regulation," measuring serum E 2 . A serum E 2 of 30 pg/ml was used Ͼ15 mm were noted 19.7% (29/147) of patients. Cysts occurred in 45% of nonsuppressed cycles and 55% of as a cutoff threshold for ovarian suppression, although various other thresholds have been used (5,7). Transvasuppressed patients. ginal sonography was performed to evaluate endometrial thickness and ovarian morphology. Endometrial thickness was measured in the central longitudinal axis DISCUSSION from the echogenic interphase of the junction of the endometrium and myometrium on the anterior to posterior wall. All patients were asked whether or not they
MATERIALS AND METHODS
There have been significant advances in COH stimulation protocols for patients programming for assisted had experienced any type of menstrual flow since GnRH-a treatment.
reproduction. A drawback to the current protocols is the extensive monitoring required to evaluate the progThe sensitivity, specificity, and positive and negative predictive values of pituitary down-regulation from ress of each cycle. Serial hormonal assays and multiple ultrasonographic exams determine the optimal timing endometrial thickness and menstrual history were calculated and compared using 2 analysis. for initiation of COH, human chorionic gonadotropin injection, and oocyte retrieval. This degree of monitorSerum samples were assayed for E 2 using a commercially available radioimmunoassy (DPC, Los Angeles, ing is time consuming, expensive, and often inconvenient for patients. CA). The sensitivity of the assay was 5.5 pg/ml, and intra-and interassay were 5.6% and 7.4%, respectively.
Many centers have amended COH protocols to simplify monitoring. A number of investigators have demonstrated that transvaginal ultrasound alone may be sufficient (4, 5) . Elimination of hormonal testing did RESULTS not adversely affect pregnancy rates or lead to higher incidence of ovarian hyperstimulation syndrome comPituitary down-regulation was achieved in 116 (79%) of the 147 treatment cycles within the 2 weeks of pared to cycles monitored in the more traditional manner. administering GnRH-a. The predictive value of menses for "suppression" was 98% (106/108), while the negaMenstrual flow to assess estrogen status has been used following a progestin challenge in amenorrheic tive predictive value in the absence of menses (no ovarian down-regulation) was 74% (29/39). Further women. The patient becomes a "bioassay," as bleeding reflects the efficacy of GnRH-a suppression of estroevaluation revealed that in IVF patients, menses occurred in 98.7% (77/78) of suppressed cycles comgen production (2). The absence of menses also has excellent negative predictive value, but not in perimenpared to 76% (29/38) of women entering of ovum donation cycles (P Ͻ 0.05). The positive predictive opausal women who are undergoing ovarian down- 
